Announcements
- OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
- ADS Program collapse
- Change of Record Time and Last Day of Dealings
- Webull Corporate Communications Service Platform
- OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
- Change of Delisting Date to 22 May 2023
- Result of Meeting
- Presentation on OK-101 at ASCRS
- OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
- First-Patient First-Visit for Phase 2 Trial
More ▼
Key statistics
On Wednesday, OKYO Pharma Ltd (OKYO:NAQ) closed at 1.41, 53.24% above the 52 week low of 0.9201 set on Jul 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.38 |
---|---|
High | 1.46 |
Low | 1.38 |
Bid | 1.38 |
Offer | 1.46 |
Previous close | 1.40 |
Average volume | 25.57k |
---|---|
Shares outstanding | 33.78m |
Free float | 25.28m |
P/E (TTM) | -- |
Market cap | 47.29m USD |
EPS (TTM) | -10.76 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 20:40 BST.
More ▼